Clinical Trials
845 trialsTherasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
Northwestern University
FORBES
Sun Yat-sen University
MOMENTUM-1
RTOG Foundation, Inc.
COLIBRI-GI
UNICANCER
PRIDE
University Hospital Tuebingen
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
BEACON
University of Birmingham
GFPC 06-2018
Centre Francois Baclesse
INTUITT-NF2
Massachusetts General Hospital
DOVE
Yonsei University
JS212 Combination Therapies in Metastatic Colorectal Cancer
Shanghai Junshi Bioscience Co., Ltd.
EAGLE
Sun Yat-sen University
CLEAR-04
Fudan University
New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
The First Hospital of Jilin University
DRIVE-II
Sun Yat-sen University
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
Third Affiliated Hospital, Sun Yat-Sen University
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Intergroupe Francophone de Cancerologie Thoracique
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
ATHENA
Centre Leon Berard
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
Samsung Medical Center
NIBCUN
Sun Yat-sen University
A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.
National Taiwan University Hospital
TROY
Yonsei University
BEST
Shanghai Zhongshan Hospital
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
EndoBARR
Medical College of Wisconsin
NIRVANA-1
ARCAGY/ GINECO GROUP
SLURP
University Medical Center Groningen
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Toco-CoR
Vejle Hospital
IMMUNOLIFE2
Gustave Roussy, Cancer Campus, Grand Paris
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis
Sun Yat-sen University
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors
Tianjin Medical University Cancer Institute and Hospital
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer
M.D. Anderson Cancer Center
SCOTI
Rutgers, The State University of New Jersey
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
TERTIO
Centre Hospitalier Universitaire de Besancon
ANGIO-TAX+
Centre Oscar Lambret
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)
University Health Network, Toronto
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
M.D. Anderson Cancer Center
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
Chinese University of Hong Kong
Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
The First Affiliated Hospital with Nanjing Medical University
Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Tianjin Medical University Cancer Institute and Hospital